Contemporary adequacy of thromboprophylaxis in acutely ill medical patients in Switzerland: a bi-centric prospective cohort.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
01 11 2023
Historique:
medline: 15 11 2023
pubmed: 13 11 2023
entrez: 13 11 2023
Statut: epublish

Résumé

Venous thromboembolism is a dreaded complication of hospitalised patients, with associated morbidity, mortality and increased healthcare costs. Previous studies have shown that pharmacological thromboprophylaxis, though effective, is inadequately administered in a large proportion of medical inpatients. Our primary aim was to evaluate the contemporary adequacy of thromboprophylaxis in medical inpatients admitted to two Swiss hospitals (a university hospital and a regional hospital). The secondary aim was to estimate the 90-day incidence of relevant thrombotic and bleeding events. In this prospective cohort, patients were recruited at the University Hospital of Geneva and the Regional Hospital of Lugano between September 2020 and February 2021 and followed for 90 days for venous thromboembolism and bleeding events. The adequacy of thromboprophylaxis (pharmacological and/or mechanical) at 24h after hospital admission was evaluated according to the simplified Geneva risk score for hospital-associated venous thromboembolism. Among 200 participants (100 at each site, mean age of 65 years), 57.5% were deemed at high risk of venous thromboembolism at admission. Thromboprophylaxis was adequate in 59.5% (95% CI 52.3-66.4%). Among high-risk and low-risk inpatients, thromboprophylaxis was adequate in 71.3% and 43.5%, respectively, with differences between sites. At 90 days, risks of adjudicated venous thromboembolism, major bleeding and mortality were 1.5%, 1.5% and 6.0%, respectively. Despite the extensive literature on thromboprophylaxis, the adequacy of thromboprophylaxis has not improved and remains insufficient among medical inpatients. Implementation and evaluation of clinical decision support systems are critically needed in this field. gov number: NCT05306821.

Sections du résumé

BACKGROUND
Venous thromboembolism is a dreaded complication of hospitalised patients, with associated morbidity, mortality and increased healthcare costs. Previous studies have shown that pharmacological thromboprophylaxis, though effective, is inadequately administered in a large proportion of medical inpatients.
STUDY AIMS
Our primary aim was to evaluate the contemporary adequacy of thromboprophylaxis in medical inpatients admitted to two Swiss hospitals (a university hospital and a regional hospital). The secondary aim was to estimate the 90-day incidence of relevant thrombotic and bleeding events.
METHODS
In this prospective cohort, patients were recruited at the University Hospital of Geneva and the Regional Hospital of Lugano between September 2020 and February 2021 and followed for 90 days for venous thromboembolism and bleeding events. The adequacy of thromboprophylaxis (pharmacological and/or mechanical) at 24h after hospital admission was evaluated according to the simplified Geneva risk score for hospital-associated venous thromboembolism.
RESULTS
Among 200 participants (100 at each site, mean age of 65 years), 57.5% were deemed at high risk of venous thromboembolism at admission. Thromboprophylaxis was adequate in 59.5% (95% CI 52.3-66.4%). Among high-risk and low-risk inpatients, thromboprophylaxis was adequate in 71.3% and 43.5%, respectively, with differences between sites. At 90 days, risks of adjudicated venous thromboembolism, major bleeding and mortality were 1.5%, 1.5% and 6.0%, respectively.
CONCLUSION
Despite the extensive literature on thromboprophylaxis, the adequacy of thromboprophylaxis has not improved and remains insufficient among medical inpatients. Implementation and evaluation of clinical decision support systems are critically needed in this field.
CLINICALTRIALS
gov number: NCT05306821.

Identifiants

pubmed: 37956238
pii: 40117
doi: 10.57187/smw.2023.40117
doi:

Substances chimiques

Anticoagulants 0

Banques de données

ClinicalTrials.gov
['NCT05306821']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

40117

Auteurs

Marco Marando (M)

Department of Internal Medicine, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Division of Pneumology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Katherine Blondon (K)

Medical Directorate, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Pauline Darbellay Farhoumand (P)

Division of General Internal Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Mathieu Nendaz (M)

Division of General Internal Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Damien Grauser (D)

Division of information systems, Geneva University Hospitals, Geneva, Switzerland.

Alain Sallet (A)

Care management, Geneva University Hospitals, Geneva, Switzerland.

Adriana Tamburello (A)

Department of Internal Medicine, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Division of Nephrology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Marco Pons (M)

Department of Internal Medicine, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Division of Pneumology, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Marc Righini (M)

Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Pietro Gianella (P)

Division of Pneumology, Regional Hospital of Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Marc Blondon (M)

Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH